An international research team has discovered a strain of gonorrhea resistant to all currently available antibiotics. This new strain is likely to transform a common and once easily treatable infection into a global threat to public health. The details of the discovery made by Dr. Magnus Unemo, Dr. Makoto Ohnishi, and colleagues will be presented at the 19th conference of the International Society for Sexually Transmitted Disease Research (ISSTDR) being held July 10-13 in Quebec City, Canada.
The team of researchers successfully identified a heretofore unknown variant of the bacterium that causes gonorrhea, Neisseria gonorrhoeae. Analyzing this new strain, dubbed H041, allowed researchers to identify the genetic mutations responsible for the bacterium's extreme resistance to all cephalosporin-class antibioticsthe last remaining drugs still effective in treating gonorrhea.
"This is both an alarming and a predictable discovery," notes Unemo of the Swedish Reference Laboratory for Pathogenic Neisseria. "Since antibiotics became the standard treatment for gonorrhea in the 1940s, this bacterium has shown a remarkable capacity to develop resistance mechanisms to all drugs introduced to control it."
"While it is still too early to assess if this new strain has become widespread, the history of newly emergent resistance in the bacterium suggests that it may spread rapidly unless new drugs and effective treatment programs are developed," Unemo adds.
Gonorrhea is one of the most common sexually transmitted diseases in the world. In the U.S. alone, according to the Centers for Disease Control and Prevention (CDC), the number of cases is estimated at 700,000 annually.
Gonorrhea is asymptomatic in about 50 percent of infected women and approximately 2 percent to 5 percent of men. When symptomatic, it is characterized by a burning sensation when urinating and pus discharge from the genitals. If left untreated, gonorrhea can lead to serious and irreversible health complications in both women and men.
In women, the infection can cause chronic pelvic pain and ectopic pregnancy. It can lead to infertility, mostly in women but also in men, and it increases the risk of HIV transmission. In 3 percent to 4 percent of cases, untreated infections spread to the skin, blood, joints, or even the heart and can cause potentially mortal lesions. Babies born of infected mothers are at high risk of developing serious blood and joint infections, and passage through the birth canal of an infected mother can cause blindness in the infant.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.